SATURN: An exploration of the dynamic interaction between IL-17, IL-17 inhibition with (secukinumab) and neutrophils in psoriatic arthritis in vitro and ex vivo with exploratory study on the potential role of Vitamin D
Phase of Trial: Phase II
Latest Information Update: 17 Oct 2017
At a glance
- Drugs Secukinumab (Primary) ; Leflunomide; Methotrexate; Sulfasalazine
- Indications Psoriatic arthritis
- Focus Pharmacodynamics
- Acronyms SATURN
- Sponsors Novartis
- 22 May 2017 Control group has been removed from the study hence treatment arms has been decreases and patients number also decreases.
- 22 May 2017 Planned number of patients changed from 30 to 20.
- 14 Oct 2016 Status changed from not yet recruiting to recruiting.